← Leaderboards
Henry Wiley
National Eye Institute
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Eye Institute
Same institution · by research overlap
Others in their field
Top investigators on “Participant”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$407,724,307
- Lawrence Corey · Fred Hutchinson Cancer Center$333,313,234
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Albert Lazzarini · California Institute Of Technology$300,431,866
Research focus
ParticipantDesignOutcome MeasureVisual AcuityEnrollmentBlindnessSafetyRetinalRetinaPrimary OutcomeProspectiveSecondary OutcomeStudy PopulationLettersAffectFollow-UpMaculaImageVisionOperative Surgical ProceduresDiabetic RetinopathyMasksIntravitreal InjectionAdverse Event
Grant awards (34)
Phase 2 Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel) (14-EI-0078, 17-EI-0136)$93,082
ZIA · FY2021 · EY · contact PI
A Phase I/IIa Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis$93,082
ZIA · FY2021 · EY · contact PI
A Phase 3 Multicenter, Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2$77,568
ZIA · FY2021 · EY · contact PI
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab (16-EI-0159)$46,541
ZIA · FY2021 · EY · contact PI
NEI Intramural Biorepository for Retinal Diseases (12-EI-0042)$201,817
ZIA · FY2020 · EY · contact PI
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab (16-EI-0159)$73,122
ZIA · FY2020 · EY · contact PI
Phase 2 Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel) (14-EI-0078, 17-EI-0136)$73,122
ZIA · FY2020 · EY · contact PI
A Phase I/IIa Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis$58,498
ZIA · FY2020 · EY · contact PI
A Phase 3 Multicenter, Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2$29,249
ZIA · FY2020 · EY · contact PI
A Phase 3 Multicenter, Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2$82,621
ZIA · FY2019 · EY · contact PI
Phase 2 Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel) (14-EI-0078, 17-EI-0136)$33,048
ZIA · FY2019 · EY · contact PI
NEI Intramural Biorepository for Retinal Diseases (12-EI-0042)$33,048
ZIA · FY2019 · EY · contact PI
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab (16-EI-0159)$30,294
ZIA · FY2019 · EY · contact PI
Clinical Trials of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel) (14-EI-0078, 17-EI-0136, 18-EI-0055) )$59,858
ZIA · FY2018 · EY · contact PI
NEI Intramural Biorepository for Retinal Diseases (12-EI-0042)$59,858
ZIA · FY2018 · EY · contact PI
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab (16-EI-0159)$57,138
ZIA · FY2018 · EY · contact PI
NEI Intramural Biorepository for Retinal Diseases (12-EI-0042)$57,757
ZIA · FY2017 · EY · contact PI
A Phase 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel) (14-EI-0078)$57,757
ZIA · FY2017 · EY · contact PI
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab (16-EI-0159)$55,132
ZIA · FY2017 · EY · contact PI
NEI Intramural Biorepository for Retinal Diseases (12-EI-0042)$57,727
ZIA · FY2016 · EY · contact PI
A Phase 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel) (14-EI-0078)$57,727
ZIA · FY2016 · EY · contact PI
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab (16-EI-0159)$55,103
ZIA · FY2016 · EY · contact PI
Phase II Study to Compare Anti-VEGF Agents in Treatment of DME (12-EI-0134)$52,479
ZIA · FY2016 · EY · contact PI
Phase II Study to Compare Anti-VEGF Agents in Treatment of DME (12-EI-0134)$101,075
ZIA · FY2015 · EY · contact PI
A Phase 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel) (14-EI-0078)$54,063
ZIA · FY2015 · EY · contact PI
NEI Intramural Biorepository for Retinal Diseases (12-EI-0042)$51,713
ZIA · FY2015 · EY · contact PI
Phase II Study to Compare Anti-VEGF Agents in Treatment of DME (12-EI-0134)$77,585
ZIA · FY2014 · EY · contact PI
A Phase 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel) (14-EI-0078)$55,764
ZIA · FY2014 · EY · contact PI
NEI Intramural Biorepository for Retinal Diseases (12-EI-0042)$53,340
ZIA · FY2014 · EY · contact PI
High Speed ICG Ranibizumab AMD (08-EI-0103)$50,915
ZIA · FY2014 · EY · contact PI
Phase II Study to Compare Anti-VEGF Agents in Treatment of DME (12-EI-0134)$78,009
ZIA · FY2013 · EY · contact PI
NEI Intramural Biorepository for Retinal Diseases (12-EI-0042)$52,006
ZIA · FY2013 · EY · contact PI
Phase II Study to Compare Anti-VEGF Agents in Treatment of DME (12-EI-0134)$53,572
ZIA · FY2012 · EY · contact PI
NEI Intramural Biorepository for Retinal Diseases (12-EI-0042)$53,572
ZIA · FY2012 · EY · contact PI